Abnormalities in chemokine levels in schizophrenia and their clinical correlates.
Abnormalities in chemokine levels in schizophrenia and their clinical correlates.
复制标题
DOI：
10.1016/j.schres.2016.09.019
复制
发表时间：
2017-03
影响因子：
4.5
通讯作者：
Jeste DV
中科院分区：
文献类型：
--
作者：
Hong S;Lee EE;Martin AS;Soontornniyomkij B;Soontornniyomkij V;Achim CL;Reuter C;Irwin MR;Eyler LT;Jeste DV
趋化因子是有希望的免疫激活和炎症的生物标志物，但精神分裂症中趋化因子异常的证据及其与临床因素的关系仍不确定。我们的目的是了解趋化因子相关的诊断差异和临床相关性，使用一个综合的小组和研究大量的，特征良好的样本成人精神分裂症和非精神分裂症。我们研究了134名门诊精神分裂症或分裂情感障碍患者和112名年龄在26至65岁之间的健康对照(HC)。采用多重免疫分析法检测血浆11种趋化因子水平。根据年龄、性别、体重指数和当前吸烟状况进行调整，测试了精神分裂症与HC在每种趋化因子上的差异。我们还检查了不同诊断组之间的年龄和性别关系是否有所不同。利用Logistic回归，我们建立了趋化因子指数(CI)，并探讨了其临床相关性。精神分裂症患者单核细胞趋化蛋白-1、巨噬细胞炎性蛋白-1β、嗜酸性粒细胞趋化蛋白-1、胸腺和活化调节趋化因子、巨噬细胞衍生趋化因子均显著高于正常对照组。调整协变量后，TARC的组间差异减小。CI是嗜酸性粒细胞趋化因子-1和MDC水平的线性组合，与年龄、精神分裂症病程和阴性症状的严重程度呈正相关。具有神经免疫调节作用的趋化因子水平在精神分裂症患者中较高，特别是在老年和慢性患者中。旨在使趋化因子水平正常化的治疗可能会随着年龄的增长改善精神分裂症患者的心理和身体健康。
Chemokines are promising biomarkers of immune activation and inflammation, but evidence for chemokine abnormalities in schizophrenia and their relationship to clinical factors remains inconclusive. We aimed to understand chemokine-related diagnostic differences and clinical correlates using a comprehensive panel and studying a large, well-characterized sample of adults with and without schizophrenia. We studied 134 outpatients with schizophrenia or schizoaffective disorder and 112 healthy comparison (HC) individuals, 26 to 65 years of age. Clinical measures were obtained, and plasma levels of 11 chemokines were assessed using multiplex immunoassay. Schizophrenia vs. HC differences were tested for each chemokine, adjusting for age, gender, body mass index, and current smoking status. We also examined whether age and gender relationships differed between diagnostic groups. Using logistic regression, we created a Chemokine Index (CI) and explored its clinical correlates. Levels of monocyte chemoattractant protein-1 (MCP-1/CCL2), macrophage inflammatory protein-1β (MIP-1β/CCL4), Eotaxin-1 (CCL11), thymus and activation-regulated chemokine (TARC/CCL17), and macrophage-derived chemokine (MDC/CCL22) were significantly higher in persons with schizophrenia than HCs. Group differences in TARC were reduced after adjusting for covariates. The CI, a linear combination of Eotaxin-1 and MDC levels, was positively associated with age, duration of schizophrenia, and severity of negative symptoms. Levels of chemokines with neuroimmune regulatory effects were higher in individuals with schizophrenia, particularly in older and chronic patients. Treatments aimed at normalizing chemokine levels might improve mental and physical health among schizophrenia patients as they age.